INAB Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Benzinga - Mentions: CERS OPRX WORX IRD ...

12 Health Care Stocks Moving In Thursday's After-Market Session

a month ago - By: IN8bio, Inc

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

a month ago - By: IN8bio, Inc

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

4 months ago - By: The Motley Fool

IN8bio (INAB) Q2 Loss Narrows 77%

4 months ago - By: IN8bio, Inc

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

5 months ago - By: Benzinga - Mentions: CDXS SLRX WVE ADIL ...

12 Health Care Stocks Moving In Thursday's After-Market Session

6 months ago - By: IN8bio, Inc

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

6 months ago - By: IN8bio, Inc

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

7 months ago - By: IN8bio, Inc

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

9 months ago - By: IN8bio, Inc

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

9 months ago - By: IN8bio, Inc

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

9 months ago - By: IN8bio, Inc

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

10 months ago - By: IN8bio, Inc

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

10 months ago - By: IN8bio, Inc

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

10 months ago - By: IN8bio, Inc

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

a year ago - By: IN8bio, Inc

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

a year ago - By: IN8bio, Inc

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

a year ago - By: IN8bio, Inc

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

a year ago - By: IN8bio, Inc

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

a year ago - By: IN8bio, Inc

IN8BIO INC (INAB) Stock News

INAB Latest News, Press Relases and Analysis

12 Health Care Stocks Moving In Thursday's After-Market Session

IN8bio Reports Third Quarter 2025 Financial Results and Recent Business Highlights

IN8bio Expands INB-100 Phase 1 Clinical Trial with Addition of The Ohio State University as New Site

IN8bio (INAB) Q2 Loss Narrows 77%

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights

12 Health Care Stocks Moving In Thursday's After-Market Session

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights

IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025

IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients

IN8bio Reports Continued Progression-Free Survival in Phase 1 Investigator-Sponsored Trial of INB-100 Allogeneic Gamma-Delta T Cells for Leukemias at the 2024 American Society of Hematology Annual Meeting

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference

IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting

IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting